LY2127399
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Jun 1, 2011 → Feb 1, 2014
NCT ID
NCT01215942About LY2127399
LY2127399 is a phase 3 stage product being developed by Eli Lilly for Rheumatoid Arthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01215942. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01576549 | Phase 2 | Terminated |
| NCT01215942 | Phase 3 | Terminated |
| NCT01200290 | Phase 2 | Completed |
| NCT01253291 | Phase 1 | Completed |
| NCT00837811 | Phase 2 | Completed |
| NCT00689507 | Phase 1 | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis